UNSPSC 51412801: Etafenone

This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0I14K589E7. European Medicines Agency schedules Etafenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07257MIG. Etafenone generally arises in the molecular formula C21H27NO2.

UNSPSC 51412801 Etafenone is a Commodity code that encompasses pharmaceutical active pharmaceutical ingredients and finished medications supplied to state and local public health agencies, fire rescue departments, and health benefit programs. Recent state and local solicitations under this code reflect demand for advanced life support medications, generic multi-source pharmaceuticals, and prescription fulfillment capabilities serving emergency medical services, state employee health plans, and cooperative purchasing alliances. The issuing bodies span city fire rescue operations, state health departments, and regional multistate cooperative purchasing organizations, with particular activity from municipal purchasing departments managing paramedic supply chains and state-level pharmacy benefit procurement.

Activity appears concentrated in Florida and Minnesota through early 2026. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue with Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials—an estimated contract value of $40,000.00 with a one-year term plus optional renewals, due April 8, 2026, and featuring a 5 percent Small Local Business Enterprise bid discount. The Minnesota Department of Administration, on behalf of the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, due March 26, 2026, with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued an exploratory RFI in late March 2026 (due April 3, 2026) regarding direct-to-manufacturer prescription programs, signaling state-level interest in alternative pharmaceutical supply and contracting models outside traditional pharmacy benefit manager and wholesaler channels.